The Vioxx debacle.
Fielder
John H
JH
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects; D017277:Drug Approval / Q000379:methods*; D004994:Ethics, Pharmacy; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D019221:Mandatory Reporting / Q000941:ethics; D009203:Myocardial Infarction / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing / Q000379:methods* / Q000639:trends; D020521:Stroke / Q000139:chemically induced*; D013450:Sulfones / Q000009:adverse effects*; D014342:Truth Disclosure / Q000941:ethics; D014481:United States; D014486:United States Food and Drug Administration / Q000941:ethics* / Q000639:trends
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib